Drug Discovery Services
Immunomics has become one of the most powerful tools for new drug discovery in a range of biomedical applications. CD Genomics provides specialized immunomics studies to clients worldwide to facilitate drug discovery programs.
Immunomics Applied in Drug Discovery
Immunomics are now very powerful new drug discovery tools for a range of biomedical applications, which can be used to identify endogenous and exogenous immune epitopes, design drugs, and re-engineer therapeutics.
- Target Identification
Based on DNA and RNA sequencing and high-throughput protein microarrays, immunomics is widely used for target identification. Immunomics is able to identify and validate endogenous epitopes such as viral, bacterial, and parasitic targets and exogenous epitopes such as cancer targets.
- Drug Designing
Immunomics integrates information from genomics, epigenetics, transcriptomics, and proteomics. This immunomics information is used for more effective and universal drug design. Taking genomics as anexample, the genome sequences of pathogens such as bacteria and viruses provide a complete genetic library of antigens or drug targets to help design effective drugs against these pathogens.
- Therapeutics Re-engineering
Immunomics informatics is widely used for immunogenicity prediction and re-engineering of protein drugs. Protein drugs now represent an important and rapidly growing area of clinical therapy for a variety of clinical indications, including autoimmune diseases, cancers, infectious diseases, and genetic disorders. Immune responses to therapeutic proteins can produce anti-drug antibodies (ADA) which may significantly affect the efficacy of the drug. In silico calculations to determine peptide-HLA affinity, in vitro measurements of peptide-MHC-II affinity, in vitro assays for antigen presentation, T cell proliferation assays, and identification of T cell epitopes are widely used in the prediction of immunogenicity.
Fig.1 Schematic diagram of the T cell-mediated immune response to a therapeutic protein. (Rosenberg, A. S., & Sauna, Z. E., 2018)
Our Services
Immunomics is now widely used in the development of vaccines for infectious diseases and cancers, as well as in the reengineering of protein therapeutics (a process now known as de-immunization), and in the fields of autoimmunity, endocrinology, allergy, transplantation, and diagnostics. CD Genomics provide target identification, drug designing, and protein therapeutics de-immunization services for our clients.
- Target Identification Service
Our company provides immunomics tools for target discovery and examination of epitope uniqueness to facilitate the development of your drugs and vaccines.
- Drug Designing Services
Depending on your specific needs, our company can help integrate immunomics information to help you design more effective drugs.
- Protein Therapeutics De-immunization Service
CD Genomics provides services for the de-immunization of functional therapeutic drugs. Based on T cell epitope analysis and prediction, we help our clients modify therapeutic proteins to reduce their potential to cause adverse antibody responses.
Why Choose Us
CD Genomics offers various types of immunomics services that provide an in-depth and comprehensive analysis of the immune system and immune processes to facilitate your drug and therapy development.
Reference
- Rosenberg, A. S., & Sauna, Z. E. (2018). Immunogenicity assessment during the development of protein therapeutics. Journal of Pharmacy and Pharmacology, 70(5), 584-594.
! For research use only.
